[1]
Zavatta G, Clarke BL. Normocalcemic Primary Hyperparathyroidism: Need for a Standardized Clinical Approach. Endocrinology and metabolism (Seoul, Korea). 2021 Jun:36(3):525-535. doi: 10.3803/EnM.2021.1061. Epub 2021 Jun 1
[PubMed PMID: 34107603]
[2]
Islam AK. Advances in the diagnosis and the management of primary hyperparathyroidism. Therapeutic advances in chronic disease. 2021:12():20406223211015965. doi: 10.1177/20406223211015965. Epub 2021 Jun 11
[PubMed PMID: 34178298]
Level 3 (low-level) evidence
[3]
Bollerslev J, Rejnmark L, Zahn A, Heck A, Appelman-Dijkstra NM, Cardoso L, Hannan FM, Cetani F, Sikjær T, Formenti AM, Björnsdottir S, Schalin-Jantti C, Belaya Z, Gibb FW, Lapauw B, Amrein K, Wicke C, Grasemann C, Krebs M, Ryhänen EM, Makay O, Minisola S, Gaujoux S, Bertocchio JP, Hassan-Smith ZK, Linglart A, Winter EM, Kollmann M, Zmierczak HG, Tsourdi E, Pilz S, Siggelkow H, Gittoes NJ, Marcocci C, Kamenicky P, 2021 PARAT Working Group. European Expert Consensus on Practical Management of Specific Aspects of Parathyroid Disorders in Adults and in Pregnancy: Recommendations of the ESE Educational Program of Parathyroid Disorders. European journal of endocrinology. 2022 Feb 1:186(2):R33-R63. doi: 10.1530/EJE-21-1044. Epub 2022 Jan 13
[PubMed PMID: 34863037]
Level 3 (low-level) evidence
[4]
Bilezikian JP, Khan AA, Potts JT Jr, Third International Workshop on the Management of Asymptomatic Primary Hyperthyroidism. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop. The Journal of clinical endocrinology and metabolism. 2009 Feb:94(2):335-9. doi: 10.1210/jc.2008-1763. Epub
[PubMed PMID: 19193908]
[5]
Bilezikian JP, Khan AA, Silverberg SJ, Fuleihan GE, Marcocci C, Minisola S, Perrier N, Sitges-Serra A, Thakker RV, Guyatt G, Mannstadt M, Potts JT, Clarke BL, Brandi ML, International Workshop on Primary Hyperparathyroidism. Evaluation and Management of Primary Hyperparathyroidism: Summary Statement and Guidelines from the Fifth International Workshop. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 2022 Nov:37(11):2293-2314. doi: 10.1002/jbmr.4677. Epub 2022 Oct 17
[PubMed PMID: 36245251]
[6]
El-Hajj Fuleihan G, Chakhtoura M, Cipriani C, Eastell R, Karonova T, Liu JM, Minisola S, Mithal A, Moreira CA, Peacock M, Schini M, Silva B, Walker M, El Zein O, Marcocci C. Classical and Nonclassical Manifestations of Primary Hyperparathyroidism. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 2022 Nov:37(11):2330-2350. doi: 10.1002/jbmr.4679. Epub 2022 Oct 17
[PubMed PMID: 36245249]
[7]
Applewhite MK, White MG, Tseng J, Mohammed MK, Mercier F, Kaplan EL, Angelos P, Vokes T, Grogan RH. Normohormonal primary hyperparathyroidism is a distinct form of primary hyperparathyroidism. Surgery. 2017 Jan:161(1):62-69. doi: 10.1016/j.surg.2016.03.038. Epub 2016 Nov 17
[PubMed PMID: 27866715]
[8]
Cusano NE, Silverberg SJ, Bilezikian JP. Normocalcemic primary hyperparathyroidism. Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry. 2013 Jan-Mar:16(1):33-9. doi: 10.1016/j.jocd.2012.12.001. Epub
[PubMed PMID: 23374739]
[9]
Shaker JL, Wermers RA. The Eucalcemic Patient With Elevated Parathyroid Hormone Levels. Journal of the Endocrine Society. 2023 Feb 9:7(4):bvad013. doi: 10.1210/jendso/bvad013. Epub 2023 Jan 26
[PubMed PMID: 36793479]
[11]
Trinh G, Rettig E, Noureldine SI, Russell JO, Agrawal N, Mathur A, Prescott JD, Zeiger MA, Tufano RP. Surgical Management of Normocalcemic Primary Hyperparathyroidism and the Impact of Intraoperative Parathyroid Hormone Testing on Outcome. Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery. 2018 Oct:159(4):630-637. doi: 10.1177/0194599818793879. Epub 2018 Aug 14
[PubMed PMID: 30105919]
[12]
Rao SD, Frame B, Miller MJ, Kleerekoper M, Block MA, Parfitt AM. Hyperparathyroidism following head and neck irradiation. Archives of internal medicine. 1980 Feb:140(2):205-7
[PubMed PMID: 7352815]
[13]
Palermo A, Naciu AM, Tabacco G, Falcone S, Santonati A, Maggi D, D'Onofrio L, Briganti SI, Castellitto D, Casini A, Pedone C, Lelli D, Fabbri A, Bilezikian JP, Napoli N, Pozzilli P, Manfrini S, Cesareo R. Clinical, Biochemical, and Radiological Profile of Normocalcemic Primary Hyperparathyroidism. The Journal of clinical endocrinology and metabolism. 2020 Jul 1:105(7):. pii: dgaa174. doi: 10.1210/clinem/dgaa174. Epub
[PubMed PMID: 32271382]
[16]
Rao DS, Wilson RJ, Kleerekoper M, Parfitt AM. Lack of biochemical progression or continuation of accelerated bone loss in mild asymptomatic primary hyperparathyroidism: evidence for biphasic disease course. The Journal of clinical endocrinology and metabolism. 1988 Dec:67(6):1294-8
[PubMed PMID: 3192682]
[17]
Bilezikian JP. Primary Hyperparathyroidism. The Journal of clinical endocrinology and metabolism. 2018 Nov 1:103(11):3993-4004. doi: 10.1210/jc.2018-01225. Epub
[PubMed PMID: 30060226]
[18]
Gómez-Ramírez J, Gómez-Valdazo A, Luengo P, Porrero B, Osorio I, Rivas S. Comparative prospective study on the presentation of normocalcemic primary hyperparathyroidism. Is it more aggressive than the hypercalcemic form? American journal of surgery. 2020 Jan:219(1):150-153. doi: 10.1016/j.amjsurg.2019.10.032. Epub 2019 Oct 22
[PubMed PMID: 31662196]
Level 2 (mid-level) evidence
[19]
Pawlowska M, Cusano NE. An overview of normocalcemic primary hyperparathyroidism. Current opinion in endocrinology, diabetes, and obesity. 2015 Dec:22(6):413-21. doi: 10.1097/MED.0000000000000198. Epub
[PubMed PMID: 26512768]
Level 3 (low-level) evidence
[20]
Carnaille BM, Pattou FN, Oudar C, Lecomte-Houcke MC, Rocha JE, Proye CA. Parathyroid incidentalomas in normocalcemic patients during thyroid surgery. World journal of surgery. 1996 Sep:20(7):830-4; discussion 834
[PubMed PMID: 8678958]
[21]
Cusano NE, Cipriani C, Bilezikian JP. Management of normocalcemic primary hyperparathyroidism. Best practice & research. Clinical endocrinology & metabolism. 2018 Dec:32(6):837-845. doi: 10.1016/j.beem.2018.09.009. Epub 2018 Sep 28
[PubMed PMID: 30665550]
[22]
Maruani G, Hertig A, Paillard M, Houillier P. Normocalcemic primary hyperparathyroidism: evidence for a generalized target-tissue resistance to parathyroid hormone. The Journal of clinical endocrinology and metabolism. 2003 Oct:88(10):4641-8
[PubMed PMID: 14557434]
[23]
Yang AH, Hsu CW, Chen JY, Tseng LM, Won GS, Lee CH. Normocalcemic primary hyperparathyroidism in patients with recurrent kidney stones: pathological analysis of parathyroid glands. Virchows Archiv : an international journal of pathology. 2006 Jul:449(1):62-8
[PubMed PMID: 16670929]
[24]
Victor F, Pereira Lemos AL, de Holanda Ribas AM, Bandeira L, Pimentel JH, de Andrade Damázio LO, Bandeira F. Occult Renal Calcifications in Patients with Normocalcemic Primary Hyperparathyroidism and Their Association with the Parathyroid Hormone-Vitamin D Axis. International journal of endocrinology. 2022:2022():4558236. doi: 10.1155/2022/4558236. Epub 2022 Apr 8
[PubMed PMID: 35437440]
[25]
Dawood NB, Yan KL, Shieh A, Livhits MJ, Yeh MW, Leung AM. Normocalcaemic primary hyperparathyroidism: An update on diagnostic and management challenges. Clinical endocrinology. 2020 Nov:93(5):519-527. doi: 10.1111/cen.14315. Epub 2020 Sep 15
[PubMed PMID: 32803770]
[30]
Leslie SW, Sajjad H, Bashir K. 24-Hour Urine Testing for Nephrolithiasis: Interpretation and Treatment Guidelines. StatPearls. 2024 Jan:():
[PubMed PMID: 29494055]
[31]
Gosavi A, Kulkarni M, Sulhyan K, Agashe S. An unusual presentation of parathyroid adenoma--a case report. Indian journal of pathology & microbiology. 2005 Apr:48(2):208-10
[PubMed PMID: 16758668]
Level 3 (low-level) evidence
[32]
Campennì A, Ruggeri RM, Sindoni A, Giovinazzo S, Calbo E, Ieni A, Calbo L, Tuccari G, Baldari S, Benvenga S. Parathyroid carcinoma presenting as normocalcemic hyperparathyroidism. Journal of bone and mineral metabolism. 2012 May:30(3):367-72. doi: 10.1007/s00774-011-0344-y. Epub 2012 Jan 14
[PubMed PMID: 22246083]
[33]
Madeo B, De Vincentis S, Repaci A, Altieri P, Vicennati V, Kara E, Vescini F, Amadori P, Balestrieri A, Pagotto U, Simoni M, Rochira V. The calcium-to-phosphorous (Ca/P) ratio in the diagnosis of primary hyperparathyroidism and hypoparathyroidism: a multicentric study. Endocrine. 2020 Jun:68(3):679-687. doi: 10.1007/s12020-020-02276-7. Epub 2020 Mar 31
[PubMed PMID: 32236819]
[34]
Madeo B, Kara E, Cioni K, Vezzani S, Trenti T, Santi D, Simoni M, Rochira V. Serum Calcium to Phosphorous (Ca/P) Ratio Is a Simple, Inexpensive, and Accurate Tool in the Diagnosis of Primary Hyperparathyroidism. JBMR plus. 2018 Mar:2(2):109-117. doi: 10.1002/jbm4.10019. Epub 2017 Nov 2
[PubMed PMID: 30283895]
[35]
Baugh KA, McCoy KL, Leung JH, Carty SE, Ramonell KM, Yip L. Normocalcemic hyperparathyroidism: Intervention to differentiate primary from secondary hyperparathyroidism. Surgery. 2024 Jan:175(1):166-171. doi: 10.1016/j.surg.2023.06.056. Epub 2023 Nov 18
[PubMed PMID: 37981554]
[36]
Guo Y, Wang Q, Lu C, Fan P, Li J, Luo X, Chen D. New parathyroid function index for the differentiation of primary and secondary hyperparathyroidism: a case-control study. BMC endocrine disorders. 2020 Jan 8:20(1):5. doi: 10.1186/s12902-019-0487-8. Epub 2020 Jan 8
[PubMed PMID: 31914999]
Level 2 (mid-level) evidence
[37]
Khan AA, Bilezikian JP, Brandi ML, Clarke BL, Gittoes NJ, Pasieka JL, Rejnmark L, Shoback DM, Potts JT, Guyatt GH, Mannstadt M. Evaluation and Management of Hypoparathyroidism Summary Statement and Guidelines from the Second International Workshop. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 2022 Dec:37(12):2568-2585. doi: 10.1002/jbmr.4691. Epub 2022 Nov 14
[PubMed PMID: 36054621]
[38]
Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, Murad MH, Weaver CM, Endocrine Society. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. The Journal of clinical endocrinology and metabolism. 2011 Jul:96(7):1911-30. doi: 10.1210/jc.2011-0385. Epub 2011 Jun 6
[PubMed PMID: 21646368]
Level 1 (high-level) evidence
[39]
Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney international. Supplement. 2009 Aug:(113):S1-130. doi: 10.1038/ki.2009.188. Epub
[PubMed PMID: 19644521]
Level 1 (high-level) evidence
[40]
Taslakian B, Trerotola SO, Sacks B, Oklu R, Deipolyi A. The Essentials of Parathyroid Hormone Venous Sampling. Cardiovascular and interventional radiology. 2017 Jan:40(1):9-21. doi: 10.1007/s00270-016-1481-4. Epub 2016 Oct 28
[PubMed PMID: 27796535]
[41]
Fiz F, Bottoni G, Massollo M, Trimboli P, Catrambone U, Bacigalupo L, Righi S, Treglia G, Imperiale A, Piccardo A. [18F]F-Choline PET/CT and 4D-CT in the evaluation of primary hyperparathyroidism: rivals or allies? The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of.... 2023 Jun:67(2):130-137. doi: 10.23736/S1824-4785.23.03514-8. Epub
[PubMed PMID: 37232932]
[42]
Sung JY. Parathyroid ultrasonography: the evolving role of the radiologist. Ultrasonography (Seoul, Korea). 2015 Oct:34(4):268-74. doi: 10.14366/usg.14071. Epub 2015 Apr 6
[PubMed PMID: 25971897]
[43]
Wilhelm SM, Wang TS, Ruan DT, Lee JA, Asa SL, Duh QY, Doherty GM, Herrera MF, Pasieka JL, Perrier ND, Silverberg SJ, Solórzano CC, Sturgeon C, Tublin ME, Udelsman R, Carty SE. The American Association of Endocrine Surgeons Guidelines for Definitive Management of Primary Hyperparathyroidism. JAMA surgery. 2016 Oct 1:151(10):959-968. doi: 10.1001/jamasurg.2016.2310. Epub
[PubMed PMID: 27532368]
[44]
Hindié E, Zanotti-Fregonara P, Tabarin A, Rubello D, Morelec I, Wagner T, Henry JF, Taïeb D. The role of radionuclide imaging in the surgical management of primary hyperparathyroidism. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2015 May:56(5):737-44. doi: 10.2967/jnumed.115.156018. Epub 2015 Apr 9
[PubMed PMID: 25858040]
[45]
Friedman K, Somervell H, Patel P, Melton GB, Garrett-Mayer E, Dackiw AP, Civelek AC, Zeiger MA. Effect of calcium channel blockers on the sensitivity of preoperative 99mTc-MIBI SPECT for hyperparathyroidism. Surgery. 2004 Dec:136(6):1199-204
[PubMed PMID: 15657576]
[46]
Kiriakopoulos A, Petralias A, Linos D. Classic Primary Hyperparathyroidism Versus Normocalcemic and Normohormonal Variants: Do They Really Differ? World journal of surgery. 2018 Apr:42(4):992-997. doi: 10.1007/s00268-018-4512-2. Epub
[PubMed PMID: 29392434]
[47]
Gungor S, Dede F, Can B, Keskin H, Aras M, Ones T, Erdil TY, Turoglu HT. The value of parathyroid scintigraphy on lesion detection in patients with normocalcemic primary hyperparathyroidism. Revista espanola de medicina nuclear e imagen molecular. 2022 Mar-Apr:41(2):86-90. doi: 10.1016/j.remnie.2020.12.007. Epub 2021 Jan 2
[PubMed PMID: 35292143]
[48]
Kluijfhout WP, Venkatesh S, Beninato T, Vriens MR, Duh QY, Wilson DM, Hope TA, Suh I. Performance of magnetic resonance imaging in the evaluation of first-time and reoperative primary hyperparathyroidism. Surgery. 2016 Sep:160(3):747-54. doi: 10.1016/j.surg.2016.05.003. Epub 2016 Jun 16
[PubMed PMID: 27318765]
[49]
Hillyar CR, Rizki H, Begum R, Gupta A, Nagabhushan N, Lee PH, Smith S. A Retrospective Cohort Study of the Utility of Ultrasound, 99mTc-Sestamibi Scintigraphy, and Four-Dimensional Computed Tomography for Pre-Operative Localization of Parathyroid Disease To Facilitate Minimally Invasive Parathyroidectomy. Cureus. 2022 Jan:14(1):e21177. doi: 10.7759/cureus.21177. Epub 2022 Jan 12
[PubMed PMID: 35165625]
Level 2 (mid-level) evidence
[50]
Cunha-Bezerra P, Vieira R, Amaral F, Cartaxo H, Lima T, Montarroyos U, Bandeira F. Better performance of four-dimension computed tomography as a localization procedure in normocalcemic primary hyperparathyroidism. Journal of medical imaging and radiation oncology. 2018 Apr 15:():. doi: 10.1111/1754-9485.12728. Epub 2018 Apr 15
[PubMed PMID: 29656552]
[51]
Hamidi M, Sullivan M, Hunter G, Hamberg L, Cho NL, Gawande AA, Doherty GM, Moore FD Jr, Nehs MA. 4D-CT is Superior to Ultrasound and Sestamibi for Localizing Recurrent Parathyroid Disease. Annals of surgical oncology. 2018 May:25(5):1403-1409. doi: 10.1245/s10434-018-6367-z. Epub 2018 Feb 26
[PubMed PMID: 29484563]
[52]
Naqvi SHS, Brooks KA, Knackstedt MI, Eguia AA, Low GM, Jacks AE, Asi KW, Patino MO, Friedman ER, Karni RJ. 4D-CT facilitates focused parathyroidectomy in patients with primary hyperparathyroidism by maintaining a high negative-predictive value for uninvolved quadrants. American journal of otolaryngology. 2020 Nov-Dec:41(6):102683. doi: 10.1016/j.amjoto.2020.102683. Epub 2020 Aug 15
[PubMed PMID: 32862032]
[53]
Kattar N, Migneron M, Debakey MS, Haidari M, Pou AM, McCoul ED. Advanced Computed Tomographic Localization Techniques for Primary Hyperparathyroidism: A Systematic Review and Meta-analysis. JAMA otolaryngology-- head & neck surgery. 2022 May 1:148(5):448-456. doi: 10.1001/jamaoto.2022.0271. Epub
[PubMed PMID: 35357400]
Level 1 (high-level) evidence
[54]
Cruz-Centeno N, Longoria-Dubocq T, Mendez-Latalladi W. Efficacy of 4D CT Scan in Re-operative Parathyroid Surgery. The American surgeon. 2022 Jul:88(7):1549-1550. doi: 10.1177/00031348221083938. Epub 2022 Mar 25
[PubMed PMID: 35337197]
[55]
Zajíčková K, Zogala D, Kubinyi J. Parathyroid imaging by (18)F-fluorocholine PET/CT in patients with primary hyperparathyroidism and inconclusive conventional methods: clinico-pathological correlations. Physiological research. 2018 Nov 28:67(Suppl 3):S551-S557
[PubMed PMID: 30484682]
[56]
Wan QC, Li JF, Tang LL, Lv J, Xie LJ, Li JP, Qin LP, Cheng MH. Comparing the diagnostic accuracy of 4D CT and 99mTc-MIBI SPECT/CT for localizing hyperfunctioning parathyroid glands: a systematic review and meta-analysis. Nuclear medicine communications. 2021 Mar 1:42(3):225-233. doi: 10.1097/MNM.0000000000001331. Epub
[PubMed PMID: 33306636]
Level 2 (mid-level) evidence
[57]
Paras C, Keller M, White L, Phay J, Mahadevan-Jansen A. Near-infrared autofluorescence for the detection of parathyroid glands. Journal of biomedical optics. 2011 Jun:16(6):067012. doi: 10.1117/1.3583571. Epub
[PubMed PMID: 21721833]
[58]
Sheu A, Diamond T. Bone mineral density: testing for osteoporosis. Australian prescriber. 2016 Apr:39(2):35-9. doi: 10.18773/austprescr.2016.020. Epub 2016 Apr 1
[PubMed PMID: 27340320]
[59]
Goel H, Binkley N, Hans D, Leslie WD. Fracture risk gradient assessed by categories of bone mineral density and trabecular bone score: the Manitoba BMD Registry. Archives of osteoporosis. 2023 May 22:18(1):73. doi: 10.1007/s11657-023-01284-0. Epub 2023 May 22
[PubMed PMID: 37213026]
[60]
Rajan R, Cherian KE, Kapoor N, Paul TV. Trabecular Bone Score-An Emerging Tool in the Management of Osteoporosis. Indian journal of endocrinology and metabolism. 2020 May-Jun:24(3):237-243. doi: 10.4103/ijem.IJEM_147_20. Epub 2020 Jun 30
[PubMed PMID: 33083262]
[61]
Silva BC, Boutroy S, Zhang C, McMahon DJ, Zhou B, Wang J, Udesky J, Cremers S, Sarquis M, Guo XD, Hans D, Bilezikian JP. Trabecular bone score (TBS)--a novel method to evaluate bone microarchitectural texture in patients with primary hyperparathyroidism. The Journal of clinical endocrinology and metabolism. 2013 May:98(5):1963-70. doi: 10.1210/jc.2012-4255. Epub 2013 Mar 22
[PubMed PMID: 23526463]
[62]
Khan AA, Hanley DA, Rizzoli R, Bollerslev J, Young JE, Rejnmark L, Thakker R, D'Amour P, Paul T, Van Uum S, Shrayyef MZ, Goltzman D, Kaiser S, Cusano NE, Bouillon R, Mosekilde L, Kung AW, Rao SD, Bhadada SK, Clarke BL, Liu J, Duh Q, Lewiecki EM, Bandeira F, Eastell R, Marcocci C, Silverberg SJ, Udelsman R, Davison KS, Potts JT Jr, Brandi ML, Bilezikian JP. Primary hyperparathyroidism: review and recommendations on evaluation, diagnosis, and management. A Canadian and international consensus. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2017 Jan:28(1):1-19. doi: 10.1007/s00198-016-3716-2. Epub 2016 Sep 9
[PubMed PMID: 27613721]
Level 3 (low-level) evidence
[64]
Cesareo R, Di Stasio E, Vescini F, Campagna G, Cianni R, Pasqualini V, Romitelli F, Grimaldi F, Manfrini S, Palermo A. Effects of alendronate and vitamin D in patients with normocalcemic primary hyperparathyroidism. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2015 Apr:26(4):1295-302. doi: 10.1007/s00198-014-3000-2. Epub 2014 Dec 19
[PubMed PMID: 25524023]
[65]
Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Tonino RP, Rodriguez-Portales JA, Downs RW, Gupta J, Santora AC, Liberman UA, Alendronate Phase III Osteoporosis Treatment Study Group. Ten years' experience with alendronate for osteoporosis in postmenopausal women. The New England journal of medicine. 2004 Mar 18:350(12):1189-99
[PubMed PMID: 15028823]
[67]
Brardi S, Ponchietti R, Duranti E. [Nephrolithiasis associated with normocalcemic or hypercalcemic primary hyperparathyroidism: focus on calciomimetics]. Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia. 2016 Nov-Dec:33(6):. pii: gin/33.6.4. Epub
[PubMed PMID: 28134399]
[68]
Bilezikian JP, Brandi ML, Eastell R, Silverberg SJ, Udelsman R, Marcocci C, Potts JT Jr. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop. The Journal of clinical endocrinology and metabolism. 2014 Oct:99(10):3561-9. doi: 10.1210/jc.2014-1413. Epub 2014 Aug 27
[PubMed PMID: 25162665]
[69]
Jorde R, Szumlas K, Haug E, Sundsfjord J. The effects of calcium supplementation to patients with primary hyperparathyroidism and a low calcium intake. European journal of nutrition. 2002 Dec:41(6):258-63
[PubMed PMID: 12474069]
[70]
Rolighed L, Rejnmark L, Sikjaer T, Heickendorff L, Vestergaard P, Mosekilde L, Christiansen P. Vitamin D treatment in primary hyperparathyroidism: a randomized placebo controlled trial. The Journal of clinical endocrinology and metabolism. 2014 Mar:99(3):1072-80. doi: 10.1210/jc.2013-3978. Epub 2014 Jan 13
[PubMed PMID: 24423366]
Level 1 (high-level) evidence
[71]
Nabata KJ, Wiseman JJ, Wiseman SM. Normohormonal primary hyperparathyroidism: A systematic review and meta-analysis. American journal of surgery. 2023 Aug:226(2):186-196. doi: 10.1016/j.amjsurg.2023.04.004. Epub 2023 Apr 19
[PubMed PMID: 37100740]
Level 1 (high-level) evidence
[72]
Kulkarni P, Goldenberg D. Surgery for Normocalcemic Hyperparathyroidism. Otolaryngologic clinics of North America. 2024 Feb:57(1):111-116. doi: 10.1016/j.otc.2023.07.012. Epub 2023 Aug 25
[PubMed PMID: 37634986]
[74]
Bilezikian JP, Silverberg SJ, Bandeira F, Cetani F, Chandran M, Cusano NE, Ebeling PR, Formenti AM, Frost M, Gosnell J, Lewiecki EM, Singer FR, Gittoes N, Khan AA, Marcocci C, Rejnmark L, Ye Z, Guyatt G, Potts JT. Management of Primary Hyperparathyroidism. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 2022 Nov:37(11):2391-2403. doi: 10.1002/jbmr.4682. Epub 2022 Oct 17
[PubMed PMID: 36054638]
[75]
Pandian TK, Lubitz CC, Bird SH, Kuo LE, Stephen AE. Normocalcemic hyperparathyroidism: A Collaborative Endocrine Surgery Quality Improvement Program analysis. Surgery. 2020 Jan:167(1):168-172. doi: 10.1016/j.surg.2019.06.043. Epub 2019 Sep 19
[PubMed PMID: 31543325]
Level 2 (mid-level) evidence
[76]
Viviani A, Colangelo L, Ciminelli BM, Novelletto A, Sonato C, Occhiuto M, Cipriani C, Diacinti D, De Martino V, Gianni W, Pepe J, Minisola S, Malaspina P. Genetic aspects underlying the normocalcemic and hypercalcemic phenotypes of primary hyperparathyroidism. Endocrine. 2023 Dec:82(3):646-653. doi: 10.1007/s12020-023-03476-7. Epub 2023 Aug 31
[PubMed PMID: 37651007]
[77]
Souberbielle JC, Cavalier E, Cormier C. How to manage an isolated elevated PTH? Annales d'endocrinologie. 2015 May:76(2):134-41. doi: 10.1016/j.ando.2015.03.005. Epub 2015 Apr 13
[PubMed PMID: 25882890]
[78]
Invernizzi M, Carda S, Righini V, Baricich A, Cisari C, Bevilacqua M. Different PTH response to oral peptone load and oral calcium load in patients with normocalcemic primary hyperparathyroidism, primary hyperparathyroidism, and healthy subjects. European journal of endocrinology. 2012 Oct:167(4):491-7. doi: 10.1530/EJE-12-0362. Epub 2012 Aug 7
[PubMed PMID: 22872468]
[79]
Zhu X, Shan C, Zhu Q, Song L, Zhou Y, Liu J, Zhang K. Clinical value of calcium load test in differential diagnosis of different types of hyperparathyroidism. International journal of clinical and experimental medicine. 2014:7(12):5445-52
[PubMed PMID: 25664054]
[81]
Shah VN, Shah CS, Bhadada SK, Rao DS. Effect of 25 (OH) D replacements in patients with primary hyperparathyroidism (PHPT) and coexistent vitamin D deficiency on serum 25(OH) D, calcium and PTH levels: a meta-analysis and review of literature. Clinical endocrinology. 2014 Jun:80(6):797-803. doi: 10.1111/cen.12398. Epub 2014 Jan 28
[PubMed PMID: 24382124]
Level 1 (high-level) evidence
[82]
Das G, Eligar V, Govindan J, Bondugulapati LN, Okosieme O, Davies S. Impact of vitamin D replacement in patients with normocalcaemic and hypercalcaemic primary hyperparathyroidism and coexisting vitamin D deficiency. Annals of clinical biochemistry. 2015 Jul:52(Pt 4):462-9. doi: 10.1177/0004563214564400. Epub 2014 Dec 2
[PubMed PMID: 25468998]
[83]
Silverberg SJ. Vitamin D deficiency and primary hyperparathyroidism. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 2007 Dec:22 Suppl 2():V100-4. doi: 10.1359/jbmr.07s202. Epub
[PubMed PMID: 18290710]
[84]
Haissaguerre M, Vantyghem MC. What an endocrinologist should know for patients receiving lithium therapy. Annales d'endocrinologie. 2022 Aug:83(4):219-225. doi: 10.1016/j.ando.2022.01.001. Epub 2022 Jan 21
[PubMed PMID: 35074396]
[85]
Lerena VS, León NS, Sosa S, Deligiannis NG, Danilowicz K, Rizzo LFL. Lithium and endocrine dysfunction. Medicina. 2022:82(1):130-137
[PubMed PMID: 35037871]
[86]
Pattan V, Singh B, Abdelmoneim SS, Gopinath C, Sundaresh V. Lithium-Induced Hyperparathyroidism: An Ill-defined Territory. Psychopharmacology bulletin. 2021 Jun 1:51(3):65-71
[PubMed PMID: 34421145]
[87]
Craus S, Mifsud EL, Mifsud S, Vella S. Management of lithium-associated hyperparathyroidism with cinacalcet hydrochloride. British journal of hospital medicine (London, England : 2005). 2023 Jan 2:84(1):1-3. doi: 10.12968/hmed.2022.0330. Epub 2023 Jan 3
[PubMed PMID: 36708345]
[88]
Corbetta S. Normocalcemic Hyperparathyroidism. Frontiers of hormone research. 2019:51():23-39. doi: 10.1159/000491036. Epub 2018 Nov 19
[PubMed PMID: 30641527]
[89]
Schini M, Jacques RM, Oakes E, Peel NFA, Walsh JS, Eastell R. Normocalcemic Hyperparathyroidism: Study of its Prevalence and Natural History. The Journal of clinical endocrinology and metabolism. 2020 Apr 1:105(4):e1171-86. doi: 10.1210/clinem/dgaa084. Epub
[PubMed PMID: 32072184]
[90]
Rodríguez-Ortiz ME, Rodríguez M. Recent advances in understanding and managing secondary hyperparathyroidism in chronic kidney disease. F1000Research. 2020:9():. pii: F1000 Faculty Rev-1077. doi: 10.12688/f1000research.22636.1. Epub 2020 Sep 1
[PubMed PMID: 32913635]
Level 3 (low-level) evidence
[91]
Yuen NK, Ananthakrishnan S, Campbell MJ. Hyperparathyroidism of Renal Disease. The Permanente journal. 2016 Summer:20(3):15-127. doi: 10.7812/TPP/15-127. Epub 2016 Jul 22
[PubMed PMID: 27479950]
[92]
Lui MS, Perrier ND. Parathyroidectomy for Normocalcemic Primary Hyperparathyroidism Improves Bone Mineral Density Regardless of Postoperative Parathyroid Hormone Levels. World journal of surgery. 2023 Mar:47(3):830-831. doi: 10.1007/s00268-022-06877-3. Epub 2023 Jan 9
[PubMed PMID: 36622434]
[93]
Pereira C. Role of intraoperative parathyroid hormone in guiding parathyroidectomy. Acta bio-medica : Atenei Parmensis. 2023 Apr 24:94(2):e2023040. doi: 10.23750/abm.v94i2.13998. Epub 2023 Apr 24
[PubMed PMID: 37092630]
[94]
Trinh G, Noureldine SI, Russell JO, Agrawal N, Lopez M, Prescott JD, Zeiger MA, Tufano RP. Characterizing the operative findings and utility of intraoperative parathyroid hormone (IOPTH) monitoring in patients with normal baseline IOPTH and normohormonal primary hyperparathyroidism. Surgery. 2017 Jan:161(1):78-86. doi: 10.1016/j.surg.2016.10.001. Epub 2016 Nov 15
[PubMed PMID: 27863787]
[95]
Ramonell KM, Lindeman B, Chen H, Fazendin J. Parathyroidectomy for Normocalcemic Tertiary Hyperparathyroidism: A 19-Year Experience. The Journal of surgical research. 2022 Aug:276():362-368. doi: 10.1016/j.jss.2022.02.011. Epub 2022 Apr 13
[PubMed PMID: 35429685]
[96]
Lemos ALP, Andrade SRL, Pontes LLH, Teixeira PMC, Bandeira E, Bandeira LC, Bandeira F. High Rate of Occult Urolithiasis in Normocalcemic Primary Hyperparathyroidism. Kidney & blood pressure research. 2019:44(5):1189-1195. doi: 10.1159/000502578. Epub 2019 Sep 20
[PubMed PMID: 31542783]
[97]
Wu KCJ, Anpalahan M. Normocalcaemic primary hyperparathyroidism: is nephrolithiasis more common than osteoporosis? Internal medicine journal. 2023 Jan:53(1):112-118. doi: 10.1111/imj.15502. Epub 2022 Jul 19
[PubMed PMID: 34435736]